Kostev F I
Biull Eksp Biol Med. 1986 Feb;101(2):147-9.
The results of 250 experiments suggest the advisability of using a new antialcoholic metabolite drug, litonit, in combined therapy of infectious-inflammatory kidney disorders occurring in alcoholism. The course of litonit injections does not only increase considerably the content of oxidized and reduced nicotinamide coenzymes, but also normalizes the number of IgA, IgG and IgM. Certain drug-induced functional and immunological shifts are now believed to indicate the increase in the functional renal capacity and enhanced kidney resistance to inflammation.
250次实验结果表明，在酒精中毒引发的感染性炎症性肾脏疾病的联合治疗中，使用一种新型抗酒精代谢物药物——利托尼特是可取的。注射利托尼特的疗程不仅能显著提高氧化型和还原型烟酰胺辅酶的含量，还能使IgA、IgG和IgM的数量恢复正常。目前认为，某些药物引起的功能和免疫变化表明肾功能增强，肾脏对炎症的抵抗力提高。
